Remdesivir, here is the US-Gilead government agreement on the price of the anti Covid drug for Americans

Remdesivir, here is the US-Gilead government agreement on the price of the anti Covid drug for Americans

Remdesivir, the first drug that has proven effective against coronavirus, will be distributed under an unusual agreement between Gilead and the US government that sets non-negotiable prices and prioritizes American patients, the New York Times writes.

Remdesivir-Gilead, here are all the news from the United States.

Remdesivir, the first drug that has proven effective against coronavirus, will be distributed under an unusual agreement with the federal government that sets non-negotiable prices and prioritizes American patients, health officials said, the New York Times reports.

The deal may serve as a model for the distribution of new treatments and vaccines in the event of a pandemic, said Ernst Berndt, a health economist at the Massachusetts Institute of Technology Sloan School of Management.

Remdesivir will sell for $ 520 per vial, or $ 3,120 per treatment cycle, to hospitals for the treatment of patients with private insurance.

The price will be set at $ 390 per ampoule, or $ 2,340 per treatment cycle, for patients with government-sponsored insurance and for those in other countries with national healthcare systems.

The drug will only be sold in the United States until September, which means that American patients will receive almost all of Gilead's production, more than 500,000 treatment cycles.

The National Health Service and state health departments have assigned the drug to hospitals across the country as needed.

After September, they will no longer have a role in determining where the drug is sent. The final cost of the drug has always been uncertain. "There is no manual on how to evaluate a new pandemic drug," said Daniel O'Day, chief executive officer of Gilead, in a statement.

The new price isn't exorbitant, many experts said. Other promising drugs now in an advanced stage of experimentation are already on the market for other purposes and cost several times more than remdesivir.

The Institute for Clinical and Economic Review, a nonprofit group that calculates fair prices for drugs, estimated that Gilead would have to charge $ 1,600 when the scheme is up to speed. But up to $ 5,080 per course of treatment would still be an affordable price for insurers, as patients could leave the hospital earlier. Critics have long accused Gilead of charging too much for innovative drugs, including early treatments for hepatitis C and Truvada, a daily pill to prevent HIV infection.

In a statement on Monday, the Institute for Clinical and Economic Review warned: "Gilead has the power to price the remdesivir at will in the United States, and no government or private insurer could ever consider leaving. from the negotiating table ".

But since many Wall Street analysts had expected the drug to cost around $ 5,000 for a course of treatment, the lower price "can be seen as a responsible decision by Gilead," added the institute.

Public Citizen, the consumer advocacy group, described the new price as offensive, noting that remdesivir was developed with more than $ 70 million in public money.

But Jalpa Doshi, of the University of Pennsylvania, noted that an advantage of remdesivir may be intangible. "This treatment and others, as well as vaccines, can help reduce fear of the virus, an important factor in accounting for its value," he said.

Just as unusual as the price of Remdesivir will be its distribution.

The plan is for Gilead to ship the drug to AmerisourceBergen, one of several drug wholesalers who fulfill orders from individual healthcare providers such as hospitals. Until the end of September, AmerisourceBergen will provide remdesivir to hospitals as needed, as described by state health departments and the Department of Health and Human Services.

After September, "once supplies are less constrained, HHS will no longer handle the assignment," said Gilead. It is unclear how patient needs will be taken into account in distribution decisions at that point.

(article taken from Epr Comunicazione's foreign press review)


This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/economia/remdesivir-ecco-laccordo-governo-usa-gilead-sul-prezzo-del-farmaco-anti-covid-per-gli-americani/ on Tue, 30 Jun 2020 06:05:24 +0000.